A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

Key facts

Sponsor

Nanjing Leads Biolabs Co.,Ltd

Principal Investigator

Lin Shen

Peking University Cancer Hospital & Institute

Intervention

LBL-024 for Injection(drug)

Enrollment

110 target

Eligibility

18 years · All sexes

Timeline

2026 – 2028

Study locations (7)

• Beijing Cancer Hospital, Beijing, Beijing Municipality, China
• AnYang Tumor Hospital, Anyang, Henan, China
• The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan, China
• Henan Cancer Hospital, Zhengzhou, Henan, China
• The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
• Shandong Cancer Hospital, Jinan, Shandong, China
• Suining Central Hospital, Suining, Sichuan, China

Collaborators

Peking University Cancer Hospital & Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the esophagus

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07457528
  Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE1NCT07503808
  A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
  IDEAYA Biosciences
• RECRUITINGPHASE2NCT07403136
  Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
  Fudan University
• RECRUITINGPHASE1, PHASE2NCT07385001
  A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
  Tang-Du Hospital
• RECRUITINGPHASE2NCT07263919
  Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
  Akeso
• RECRUITINGPHASE2NCT07481058
  KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
  Beijing Konruns Pharmaceutical Co., Ltd.
• RECRUITINGPHASE1NCT07217171
  A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
  EvolveImmune United, Inc
• ENROLLING BY INVITATIONPHASE2NCT07312578
  Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
  Peking University

See all trials for Squamous cell carcinoma of the esophagus →